

## PATENT ASSIGNMENT

Electronic Version v1.1  
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
BELLUS Health Inc.	05/25/2012
RECEIVING PARTY DATA	
Name:	BHI LIMITED PARTNERSHIP
Street Address:	275 Armand-Frappier Boulevard
City:	Laval, Quebec
State/Country:	CANADA
Postal Code:	H7V 4A7
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	12362971
CORRESPONDENCE DATA	
Fax Number:	7032436410
Phone:	(703)243-6333
Email:	mail@mwzb.com
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i>	
Correspondent Name:	Millen White Zelano & Branigan, PC
Address Line 1:	2200 Clarendon Boulevard
Address Line 2:	Suite 1400
Address Line 4:	Arlington, VIRGINIA 22201
ATTORNEY DOCKET NUMBER:	BELLUS-0003-A-C01 (KLB)
NAME OF SUBMITTER:	Anthony J. Zelano
Total Attachments: 3 source=BELLUS-0003-A-C01_Assign_BHInc-BHI-LP#page1.tif source=BELLUS-0003-A-C01_Assign_BHInc-BHI-LP#page2.tif source=BELLUS-0003-A-C01_Assign_BHInc-BHI-LP#page3.tif	

OP \$40.00 12362971

PATENT

## ASSIGNMENT

BELLUS HEALTH INC., a Corporation organized under the Canada Business Corporations Act, having its principal place of business at 275 Armand-Frappier Boulevard, Laval, Québec, H7V 4A7, Canada, (the "Assignor") in consideration of valuable consideration paid to it by:

### BHI LIMITED PARTNERSHIP

a limited partnership constituted pursuant to the laws of the Province of Québec, Canada, having its principal place of business at 275 Armand-Frappier Boulevard, Laval, Québec, H7V 4A7, Canada, the receipt of which is hereby acknowledged, does hereby sell, assign and transfer unto said

### BHI LIMITED PARTNERSHIP

its successors and assigns (collectively the "Assignee"), the entire interest for Canada, the United States of America, and all foreign countries in certain invention(s) or improvement(s) described in the Patents and Applications listed in Schedule A, including all rights of priority under the International Convention for the Protection of Industrial Property, in any Patent Office, and in all Letters Patent in any country which may or shall be granted on said invention, or any parts thereof, or on said application, or any divisional, continuation, continuation-in-part, reexamination, reissue, national phase, regional phase, validation, or other applications or patents based in whole or in part thereon, the same to be held and enjoyed by the Assignee, for its own use and benefit and the use and benefit of its successors, legal representatives and assigns, to the full end of the term or terms for which Letters Patent may be granted or extended, as fully and entirely as the same would have been held and enjoyed by the Assignor had this assignment not been made. And the Assignor agrees, for itself and its successors and assigns, with the Assignee and its successors and assigns but at its or their expense and charges, hereafter to execute all applications, amended specifications, deed or other instrument, and to do all acts necessary or proper to secure the grant of Letters Patent in Canada, the United States and in all other countries to the Assignee, with specifications and claims in such form as shall be approved by the counsel of said Assignee and to vest and confirm in the Assignee the legal title to all such Patents and Applications.

And the Assignor does hereby authorize and request the Commissioner of Patents and Trademarks of Canada, the United States and all other Patent Offices to issue such Letters Patent as shall be granted upon said application or applications based thereon to the Assignee.

On behalf of BELLUS HEALTH INC.:

Date: May 25, 2012


Witness:


Date: May 25, 2012


Date: May 25, 2012


Witness:

Date: May 25, 2012

  
Name: Roberto Bellini  
Title: President

  
Name: Nicole Picher

  
Name: François Desjardins  
Title: Vice-President, Finance


  
Name: NICOLE TIMBRO



On behalf of 8103968 CANADA INC., in its capacity as general partner of BHI Limited Partnership:

Date: May 25, 2012

Witness:

Date: May 25, 2012

  
Name: Roberto Bellini  
Title: President

  
  
Name: NICOLE TIMBRO

# SCHEDULE A

## 030 – Pharmaceutical Formulations of Amyloid-Inhibiting Compounds

Country	Application No. (Publication No.)	Grant No.
U.S.A.	60/480,984	
U.S.A.	60/512,116	
U.S.A.	10/871,549	
U.S.A.	60/640,108	
U.S.A.	11/103,656	
U.S.A.	12/362,971	
PCT	PCT/IB2004/002381 (WO2004/112762)	
Australia	2004248995	2004248995
Brazil	PI0411808-1	
Canada	2,529,268	
China	200480024244.8	
Europe	04 744 039.1	1 635 799
Austria	EP 04 744 039.1	EP 1 635 799
Belgium	EP 04 744 039.1	EP 1 635 799
Switzerland	EP 04 744 039.1	EP 1 635 799
Czech Republic	EP 04 744 039.1	EP 1 635 799
Germany	EP 04 744 039.1	602004022408.1-08
Denmark	EP 04 744 039.1	EP 1 635 799
Spain	EP 04 744 039.1	EP 1 635 799
Finland	EP 04 744 039.1	EP 1 635 799
France	EP 04 744 039.1	EP 1 635 799
United Kingdom	EP 04 744 039.1	EP 1 635 799
Greece	EP 04 744 039.1	EP 1 635 799
Hungary	EP 04 744 039.1	EP 1 635 799
Ireland	EP 04 744 039.1	EP 1 635 799
Italy	EP 04 744 039.1	EP 1 635 799
Luxembourg	EP 04 744 039.1	EP 1 635 799
Monaco	EP 04 744 039.1	EP 1 635 799
Netherlands	EP 04 744 039.1	EP 1 635 799
Poland	EP 04 744 039.1	EP 1 635 799
Portugal	EP 04 744 039.1	EP 1 635 799
Romania	EP 04 744 039.1	EP 1 635 799
Sweden	EP 04 744 039.1	EP 1 635 799
Slovenia	EP 04 744 039.1	EP 1 635 799
Slovak Republic	EP 04 744 039.1	EP 1 635 799
Turkey	EP 04 744 039.1	TR 2009 07634 T4
Hong Kong	07101022.3	
India	251/CHENP/2006	234091
Israel	172193	172193
Japan	2006-516600	4,903,561
Mexico	PA/a/2005/013974	267678
New Zealand	544685	544685